tert-butyl (R)-17-(tert-butoxycarbonyl)-16-(cyclohexylmethyl)-14-cyclopentyl-6-imino-2,2-dimethyl-4,8,12,15-tetraoxo-3-oxa-5,7,11,14,17-pentaazanonadecan-19-oate | 194985-18-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (R)-17-(tert-butoxycarbonyl)-16-(cyclohexylmethyl)-14-cyclopentyl-6-imino-2,2-dimethyl-4,8,12,15-tetraoxo-3-oxa-5,7,11,14,17-pentaazanonadecan-19-oate
• CAS: 194985-18-7
• 化学式: C₃₆H₆₂N₆O₉
• 分子量: 722.923
• InChiKey: LKWJAAJCWQEULN-AREMUKBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.76
• 重原子数：
  51.0
• 可旋转键数：
  12.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  196.53
• 氢给体数：
  4.0
• 氢受体数：
  10.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (R)-17-(tert-butoxycarbonyl)-16-(cyclohexylmethyl)-14-cyclopentyl-6-imino-2,2-dimethyl-4,8,12,15-tetraoxo-3-oxa-5,7,11,14,17-pentaazanonadecan-19-oate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以85%的产率得到HOCOCH2-D-Cha-N(cPent)Gly-bAla-guanidino
  参考文献：
  名称：

  Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety

  摘要：

  Replacement of the noragmatine group in thrombin inhibitors with a beta-alanyl-guanidine group resulted in a nearly equipotent and more selective compound 8 despite the fact that the pK(a) of this P-1 moiety is five orders of magnitude lower. Further modification resulted in a nonpeptide inhibitor with this beta-alanyl guanidine group, compound 28. This is an active and selective thrombin inhibitor and in view of its nonpeptide/low basicity structure selected for further pharmacological studies. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00650-7
• 作为产物：
  描述：

  N-(tert-butyloxycarbonylmethyl)-D-Cha-OMe 在 sodium hydroxide 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl (R)-17-(tert-butoxycarbonyl)-16-(cyclohexylmethyl)-14-cyclopentyl-6-imino-2,2-dimethyl-4,8,12,15-tetraoxo-3-oxa-5,7,11,14,17-pentaazanonadecan-19-oate
  参考文献：
  名称：

  Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety

  摘要：

  Replacement of the noragmatine group in thrombin inhibitors with a beta-alanyl-guanidine group resulted in a nearly equipotent and more selective compound 8 despite the fact that the pK(a) of this P-1 moiety is five orders of magnitude lower. Further modification resulted in a nonpeptide inhibitor with this beta-alanyl guanidine group, compound 28. This is an active and selective thrombin inhibitor and in view of its nonpeptide/low basicity structure selected for further pharmacological studies. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00650-7